newsfilter
← Latest News
GlobeNewswire·

Entasis Therapeutics Announces Year End 2021 Financial Results and Provides Business Update

Phase 3 ATTACK registrational trial for sulbactam-durlobactam (SUL-DUR) achieved all primary and secondary endpoints, NDA submission planned for mid-2022 Zoliflodacin Phase 3 trial progressing; enrollment completion now anticipated in 2023 Entasis' pa